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Abstract
Parkinsonism-dystonia is rare in carriers of PRNP P102L mutation. Severity and distribution of 
prion protein (PrP) deposition may influence the clinical presentation. We present such clinic-
pathological correlation in a 56-year-old male with a PRNP P102L mutation associated with a 
phenotype characterized by rapidly progressing parkinsonism-dystonia. The patient was studied 
clinically (videotaped exams, brain MRIs); molecular genetically (gene sequence analysis); and 
neuropathologically (histology, immunohistochemistry) during his 7-month disease course. The 
patient had parkinsonism, apraxia, aphasia, and dystonia, which progressed rapidly. Molecular 
genetic analysis revealed PRNP P102L mutation carrier status. Brain MRIs revealed progressive 
global volume loss and T2/FLAIR hyperintensity in neocortex and basal ganglia. Postmortem 
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examination showed neuronal loss, gliosis, spongiform changes, and PrP deposition in the 
striatum. PrP immunohistochemistry revealed widespread severe PrP deposition in the thalamus 
and cerebellar cortex. Based on the neuropathological and molecular-genetic analysis, the rapidly 
progressing parkinsonism-dystonia correlated with nigrostriatal, thalamic, and cerebellar 
pathology.
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Introduction
Gerstmann-Sträussler-Scheinker disease (GSS) is a rare, adult onset, autosomal-dominant 
neurodegenerative prion disease. Genetically, GSS is associated with a variety of point 
mutations in the Prion Protein gene (PRNP).1 The most common mutation identified among 
affected subjects is P102L in which the pathogenic PRNP has a proline-to-leucine 
substitution at codon 102 (P102L). 1, 2 The clinical phenotype of GSS associated with the 
P102L mutation shows a high degree of heterogeneity. However, it is predominantly 
characterized by progressive ataxia, pyramidal signs, and dementia over a course lasting 
several years. Pathologically, GSS is characterized by deposits of prion protein (PrP) in the 
form of diffuse and amyloid plaques in the central nervous system (CNS).2-4 Prominent 
parkinsonism and dystonia are not typical in subjects carrying the P102L mutation. We 
herein present a PRNP P102L mutation carrier demonstrating a clinical presentation 
characterized by rapidly progressive parkinsonism-dystonia. We describe the 
clinicopathological features in this case and discuss the possible mechanism of this unique 
clinical presentation.
Methods
Clinical evaluations were carried out via detailed, videotaped, longitudinal movement 
disorder neurology examinations, EEG, and serial brain magnetic resonance imaging (MRI). 
Videotaping was performed with the patient's informed consent. Molecular genetic 
assessments were accomplished using gene sequence analysis and neuropathological 
examination was performed using standard histological and immunohistochemical 
techniques.
Results
A 56 year-old-man presented with initial symptoms of bradykinesia, right arm rigidity, 
intermittent resting tremor and gait imbalance. Two months after the onset of symptoms, he 
developed memory impairment and expressive dysphasia with decreased verbal fluency. He 
had rapid functional decline and required assistance with his daily living activities. He was 
evaluated at the Johns Hopkins Movement Disorder Clinic three months after the onset of 
symptoms. On motor exam, he had bradykinesia, moderate right arm rigidity with dystonic 
forearm flexor posturing, and dystonic right thumb flexion. His gait exam showed evidence 
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of decreased arm swing and postural instability (Video 1). Furthermore, he had dysphasia, 
dysarthria, memory impairment, and apraxia.
Further investigation revealed that he had several family members that had been previously 
diagnosed with Gerstmann-Sträussler-Scheinker disease (Figure 1). Molecular genetic 
analysis revealed that he was a PRNP P102L-129M mutation carrier and heterozygous for 
M/V polymorphism at codon 129. Sequential high resolution brain MRI showed progressive 
cerebral and cerebellar volume loss and T2/FLAIR hyperintensity in the neocortex and basal 
ganglia (Figure 2).5
Subsequently, he had a rapid decline with progressive aphasia, bradykinesia, rigidity and 
dystonia leading to a bed-bound state, and death within 7 months of the onset of symptoms.
Neuropathological evaluation revealed moderate nigral neuronal loss and severe neuronal 
loss, gliosis, spongiform changes, and PrP deposition in the dentate and striatum (Figure 2). 
In the cerebral cortex, neuronal loss, gliosis, spongiform changes and PrP deposition 
involved more severely the parietal than the frontal cortex. PrP immunohistochemistry 
revealed widespread severe PrP deposition in the thalamus and cerebellar cortex. Alpha-
synuclein and tau immunostaining of the substantia nigra were carried out to rule out 
incidental synucleinopathy or tauopathy contributing to the Parkinsonism. Both alpha-
synuclein and tau immunostaining were negative (data not shown). Western blot 
characterization of the protease-resistant prion protein (PrPres) showed three major bands of 
21, 27 and 30 kDa together with an 8 kDa fragment, typically present in GSS-P102L (Figure 
3).
Discussion
To expand upon the clinicopathological phenotype observed in GSS associated with PRNP 
P102L mutation, we describe a case with a rapid clinical progression and a severe movement 
disorder. In fact, the severe PrP deposition and spongiform changes in the substantia nigra, 
striatum, thalamus, and cerebellum may well correlate with this patient's clinical 
presentation characterized by impairment of motor control, parkinsonism, and dystonia.
Clinical and pathological heterogeneity is known to occur in GSS. Even in subjects with 
P102L mutations, phenotypic variations can be seen. PRNP P102L mutation carriers may 
present with cerebellar ataxia, dementia, pyramidal signs and rarely parkinsonism.6 In 
P102L carriers, disease duration ranges from 1 to 10 years with the age of onset variable 
from the 40s to the 70s.6 In a recent report of atypical parkinsonism in GSS, clinical 
heterogeneity in a family pedigree with the same Y218N mutation in the PRNP gene was 
described, suggesting that there are a variety of factors influencing the clinical phenotype.7 
While the authors describe a GSS case with a Y218N mutation in the PRNP gene with 
atypical parkinsonism mimicking progressive supranuclear palsy,7 our case showed a more 
rapidly progressing parkinsonism-dystonia in a PRNP P102L mutation carrier. In GSS, PrP 
deposits resulting from degradation products found in the cerebral/cerebellar cortices and in 
the basal ganglia are characteristic pathological findings, however, spongiform changes and 
neuronal loss are also frequently seen.3, 6 The severity and extent of pathological changes 
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may not easily explain the rapid clinical course, which in turn might be better explained by 
distribution and toxicity of the PrPSc.
The basis for the variable clinicopathological phenotypes observed in GSS is not fully 
understood, but several mechanisms have been postulated. Polymorphisms in PrP, including 
either methionine or valine at residue 129, are proposed to influence the clinical and 
pathological phenotype.3 Additionally, variations in the anatomical distribution of 
pathologic PrP may account for the phenotypic differences seen among individuals carrying 
the same mutation.8 Finally, in GSS P102L, the presence of proteinase-K resistant PrP 
isoforms of molecular weight 21-30 kDa have been associated with pathologic phenotypes 
characterized by significant spongiform degeneration.9
In the initial evaluation of patients with suspected GSS, a broad differential diagnosis should 
be considered including corticobasal syndrome (CBS) which can present with similar 
clinical signs. Features of CBS include parkinsonian rigidity, dystonia, apraxia and cognitive 
impairment,10, 11 similar to the presenting features of our case. Further investigations 
including brain MRI and genetic testing can aid in narrowing the diagnosis between these 
neurodegenerative conditions.
We present a GSS phenotype characterized by a rapid progression on the disease and by a 
movement disorder with symptoms of parkinsonism-dystonia. Based on clinical, imaging, 
and neuropathologic data obtained from the study of this patient, we hypothesize that the 
clinical manifestations, dominated by rapid progression and prominent movement disorder, 
may result from an early seeding and spread of a very toxic form of PrPSc within basal 
ganglia, substantia nigra, and cerebellum.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Funding Sources: Part of this work was done with support from grants from the National Institutes of Health 
(NIH) (P01 AG14359 and P30 AG 010133) and Centers for Disease Control and Prevention (CDC) 
(1U51CK000100).
Financial Disclosures for the previous 12 months: Dr. Mari has received consultancy fees from Navidea 
Biopharmaceuticals. Dr. Umeh reports receiving research grants from the BWH Parkinson's Research Fund.
References
1. Hsiao K, Baker HF, Crow TJ, et al. Linkage of a prion protein missense variant to Gerstmann-
Sträussler syndrome. Nature. 1989; 338(6213):342–345. [PubMed: 2564168] 
2. Ghetti B, Piccardo P, Frangione B, et al. Prion protein amyloidosis. Brain Pathol. 1996; 6(2):127–
145. [PubMed: 8737929] 
3. Bugiani O, Giaccone G, Piccardo P, Morbin M, Tagliavini F, Ghetti B. Neuropathology of 
Gerstmann-Sträussler-Scheinker disease. Microsc Res Tech. 2000; 50(1):10–15. [PubMed: 
10871543] 
4. Ghetti B, Tagliavini F, Takao M, Bugiani O, Piccardo P. Hereditary prion protein amyloidoses. Clin 
Lab Med. 2003; 23(1):65–85. viii. [PubMed: 12733425] 
Umeh et al. Page 4
Mov Disord Clin Pract. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
5. Parchi P, Chen SG, Brown P, et al. Different patterns of truncated prion protein fragments correlate 
with distinct phenotypes in P102L Gerstmann-Straussler-Scheinker disease. Proc Natl Acad Sci U S 
A. 1998; 95(14):8322–8327. [PubMed: 9653185] 
6. Ghetti B, Tagliavini F, Kovacs GG, Piccardo P. Gerstmann–Sträussler–Scheinker Disease. 
Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders: Wiley-
Blackwell. 2011:364–377.
7. Ribosa-Nogué R, Pagonabarraga J, Gomez-Anson B, Granell-Moreno E, Sánchez-Valle R, 
Kulisevsky J. Gerstmann-Sträussler-Scheinker Disease Presenting with Atypical Parkinsonism, but 
Typical Magnetic Resonance Imaging Findings of Prion Disease. Movement Disorders Clinical 
Practice. 2015
8. Wadsworth JD, Joiner S, Linehan JM, et al. Phenotypic heterogeneity in inherited prion disease 
(P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion 
protein. Brain. 2006; 129(Pt 6):1557–1569. [PubMed: 16597650] 
9. Piccardo P, Dlouhy SR, Lievens PM, et al. Phenotypic variability of Gerstmann-Straussler-Scheinker 
disease is associated with prion protein heterogeneity. J Neuropathol Exp Neurol. 1998; 57(10):
979–988. [PubMed: 9786248] 
10. Chahine LM, Rebeiz T, Rebeiz JJ, Grossman M, Gross RG. Corticobasal syndrome: Five new 
things. Neurol Clin Pract. 2014; 4(4):304–312. [PubMed: 25279254] 
11. Alexander SK, Rittman T, Xuereb JH, Bak TH, Hodges JR, Rowe JB. Validation of the new 
consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry. 
2014; 85(8):925–929. [PubMed: 24521567] 
Umeh et al. Page 5
Mov Disord Clin Pract. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Family pedigree. Case is indicated by the arrow. There were seven family members with 
symptoms consistent with GSS disease. Five family members were positive for the GSS 
mutation. One family member with a positive GSS mutation had no symptoms at time of 
testing (age 23). Mean age at symptom onset was 45. Clinical phenotypes of affected family 
members included ataxia, cognitive impairment, and dysarthria.
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Figure 2. 
Brain MRI shows increased signal in multiple cortical and basal ganglia regions on diffusion 
(E) and T2 FLAIR (F) sequences. Cerebral (E-F) and cerebellar (G) atrophy is also present. 
Severe spongiform changes shown on H&E stain in the caudate (A) and frontal cortex (H), 
indicated by vacuoles in the neuropil (arrows). Note eosinophilic amyloid cores (blue 
arrowheads). Widespread PrP deposits are shown in the caudate (B), thalamus (K), frontal 
(I)/parietal (J) cortices (3F4 antibodies), substantia nigra (C, 3F4 antibodies), as well as the 
cerebellum (D, 12F10 antibodies)
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Figure 3. 
Detection and characterization of protease-resistant prion protein (PrPres): Immunoblot of 
total homogenates (TH), treated with proteinase K, obtained from the frontal cortex of the 
present case and of the most common sCJD subtypes, sCJD-MM1 and sCJD-VV2 
(representing PrPres types 1 and 2, respectively). Membranes were probed with monoclonal 
antibodies (mAbs) 3F4 (amino acids 109-112) and 12B2 (amino acids 89-93). PrPres of the 
present case includes an 8 kDa fragment, typically present in GSS-P102L. This fragment is 
much more visible when probed with 12B2, a type 1-specific antibody.
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